CYP2D6 and neoplasm: In general, tumour organoids identified as CYP2D6 intermediate metabolizers were more sensitive to talazoparib than normal metabolizers (Fig. 5d), supporting its potential as therapy for heterozygous patients only retaining the LoF allele in their tumors.